{
  "id": [
    "24040153"
  ],
  "source": [
    "MED"
  ],
  "pmid": [
    "24040153"
  ],
  "pmcid": [
    "PMC3764029"
  ],
  "fullTextIdList": [
    {
      "fullTextId": [
        "PMC3764029"
      ]
    }
  ],
  "doi": [
    "10.1371/journal.pone.0074027"
  ],
  "title": [
    "Sensitivity of a ribavirin resistant mutant of hepatitis C virus to other antiviral drugs."
  ],
  "authorString": [
    "Mihalik KB, Feigelstock DA."
  ],
  "authorList": [
    {
      "author": [
        {
          "fullName": [
            "Mihalik KB"
          ],
          "firstName": [
            "Kathleen B"
          ],
          "lastName": [
            "Mihalik"
          ],
          "initials": [
            "KB"
          ],
          "authorAffiliationsList": [
            {
              "authorAffiliation": [
                "Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, United States of America."
              ]
            }
          ]
        },
        {
          "fullName": [
            "Feigelstock DA"
          ],
          "firstName": [
            "Dino A"
          ],
          "lastName": [
            "Feigelstock"
          ],
          "initials": [
            "DA"
          ]
        }
      ]
    }
  ],
  "dataLinksTagsList": [
    {
      "dataLinkstag": [
        "altmetrics",
        "supporting_data"
      ]
    }
  ],
  "journalInfo": [
    {
      "issue": [
        "9"
      ],
      "volume": [
        "8"
      ],
      "journalIssueId": [
        "2074012"
      ],
      "dateOfPublication": [
        "2013 "
      ],
      "monthOfPublication": [
        "0"
      ],
      "yearOfPublication": [
        "2013"
      ],
      "printPublicationDate": [
        "2013-01-01"
      ],
      "journal": [
        {
          "title": [
            "PloS one"
          ],
          "ISOAbbreviation": [
            "PLoS ONE"
          ],
          "medlineAbbreviation": [
            "PLoS One"
          ],
          "NLMid": [
            "101285081"
          ],
          "ISSN": [
            "1932-6203"
          ],
          "ESSN": [
            "1932-6203"
          ]
        }
      ]
    }
  ],
  "pubYear": [
    "2013"
  ],
  "pageInfo": [
    "e74027"
  ],
  "abstractText": [
    "BACKGROUND: While ribavirin mono-therapy regimens have minimal effect on patients with chronic hepatitis C virus (HCV) infections, they can be efficacious when combined with interferon. Clinical studies show that interferon-free combination therapies containing ribavirin are also efficacious, suggesting that an interferon-free therapy could be adopted in the near future. However, generation of drug resistant mutants and cross resistance to other drugs could impair the efficacy of the treatment. Therefore, understanding the mechanism of HCV resistance to ribavirin and cross resistance to other antiviral drugs could be of major importance. METHODS: We tested the ability of a J6/JFH1 derived HCV ribavirin resistant mutant to grow in tissue cultured Huh7D cells in the presence of the mutagen 5-Fluorouracil and the nucleoside analog 2'-C-Methylcytidine. Virus replication was assessed by detecting HCV antigens by immunofluorescence and by titrating virus present in the supernatants. Recovered viruses were amplified by RT-PCR and sequenced. RESULTS: The sensitivity of HCV-RR relative to parental J6/JFH1 to the tested drugs varied. HCV-RR was more resistant than J6/JFH1 to 5-Fluorouracil but was not more resistant than J6/JFH1 to 2'-C-Methylcytidine. Growth of HCV-RR in 5-Fluorouracil allowed the selection of an HCV-RR derived mutant resistant to 5-Fluorouracil (HCV-5FU). HCV-5FU grows to moderate levels in the presence of high concentrations of 5-Fluorouracil and to parental levels in the absence of the drug. Sequence of its genome shows that HCV-5FU accumulated multiple synonymous and non-synonymous mutations. CONCLUSIONS: These results indicate that determinants of resistance to ribavirin could also confer resistance to other anti-HCV drugs, shedding light toward understanding the mechanism of action of ribavirin and highlighting the importance of combination drug selection for HCV treatment. The results also show that it is possible to select a 5-Fluorouracil HCV resistant mutant that replicates to levels similar to parental virus when grown in the absence of 5-Fluorouracil."
  ],
  "affiliation": [
    "Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, United States of America."
  ],
  "publicationStatus": [
    "epublish"
  ],
  "language": [
    "eng"
  ],
  "pubModel": [
    "Electronic-eCollection"
  ],
  "pubTypeList": [
    {
      "pubType": [
        "Research Support, U.S. Gov't, P.H.S.",
        "research-article",
        "Journal Article"
      ]
    }
  ],
  "meshHeadingList": [
    {
      "meshHeading": [
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Cell Line"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Humans"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Hepacivirus"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                },
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Hepatitis C, Chronic"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DT"
                  ],
                  "qualifierName": [
                    "drug therapy"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "VI"
                  ],
                  "qualifierName": [
                    "virology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Fluorouracil"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Viral Proteins"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "GE"
                  ],
                  "qualifierName": [
                    "genetics"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "CH"
                  ],
                  "qualifierName": [
                    "chemistry"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Cytidine"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "AA"
                  ],
                  "qualifierName": [
                    "analogs & derivatives"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                },
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Ribavirin"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                },
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Antiviral Agents"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "PD"
                  ],
                  "qualifierName": [
                    "pharmacology"
                  ],
                  "majorTopic_YN": [
                    "Y"
                  ]
                },
                {
                  "abbreviation": [
                    "TU"
                  ],
                  "qualifierName": [
                    "therapeutic use"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Microbial Sensitivity Tests"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Amino Acid Substitution"
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Drug Resistance, Viral"
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Virus Replication"
          ],
          "meshQualifierList": [
            {
              "meshQualifier": [
                {
                  "abbreviation": [
                    "DE"
                  ],
                  "qualifierName": [
                    "drug effects"
                  ],
                  "majorTopic_YN": [
                    "N"
                  ]
                }
              ]
            }
          ]
        },
        {
          "majorTopic_YN": [
            "N"
          ],
          "descriptorName": [
            "Kinetics"
          ]
        },
        {
          "majorTopic_YN": [
            "Y"
          ],
          "descriptorName": [
            "Mutation"
          ]
        }
      ]
    }
  ],
  "chemicalList": [
    {
      "chemical": [
        {
          "name": [
            "Antiviral Agents"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "Viral Proteins"
          ],
          "registryNumber": [
            "0"
          ]
        },
        {
          "name": [
            "2'-C-methylcytidine"
          ],
          "registryNumber": [
            "27FS20C1D8"
          ]
        },
        {
          "name": [
            "Fluorouracil"
          ],
          "registryNumber": [
            "U3P01618RT"
          ]
        },
        {
          "name": [
            "Ribavirin"
          ],
          "registryNumber": [
            "49717AWG6K"
          ]
        },
        {
          "name": [
            "Cytidine"
          ],
          "registryNumber": [
            "5CSZ8459RP"
          ]
        }
      ]
    }
  ],
  "subsetList": [
    {
      "subset": [
        {
          "code": [
            "IM"
          ],
          "name": [
            "Index Medicus"
          ]
        }
      ]
    }
  ],
  "fullTextUrlList": [
    {
      "fullTextUrl": [
        {
          "availability": [
            "Free"
          ],
          "availabilityCode": [
            "F"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "PubMedCentral"
          ],
          "url": [
            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24040153/?tool=EBI"
          ]
        },
        {
          "availability": [
            "Free"
          ],
          "availabilityCode": [
            "F"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "PubMedCentral"
          ],
          "url": [
            "https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24040153/pdf/?tool=EBI"
          ]
        },
        {
          "availability": [
            "Subscription required"
          ],
          "availabilityCode": [
            "S"
          ],
          "documentStyle": [
            "doi"
          ],
          "site": [
            "DOI"
          ],
          "url": [
            "https://doi.org/10.1371/journal.pone.0074027"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "html"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC3764029"
          ]
        },
        {
          "availability": [
            "Open access"
          ],
          "availabilityCode": [
            "OA"
          ],
          "documentStyle": [
            "pdf"
          ],
          "site": [
            "Europe_PMC"
          ],
          "url": [
            "https://europepmc.org/articles/PMC3764029?pdf=render"
          ]
        }
      ]
    }
  ],
  "isOpenAccess": [
    "Y"
  ],
  "inEPMC": [
    "Y"
  ],
  "inPMC": [
    "Y"
  ],
  "hasPDF": [
    "Y"
  ],
  "hasBook": [
    "N"
  ],
  "hasSuppl": [
    "Y"
  ],
  "citedByCount": [
    "3"
  ],
  "hasData": [
    "Y"
  ],
  "hasReferences": [
    "Y"
  ],
  "hasTextMinedTerms": [
    "Y"
  ],
  "hasDbCrossReferences": [
    "N"
  ],
  "hasLabsLinks": [
    "Y"
  ],
  "authMan": [
    "N"
  ],
  "epmcAuthMan": [
    "N"
  ],
  "nihAuthMan": [
    "N"
  ],
  "hasTMAccessionNumbers": [
    "Y"
  ],
  "tmAccessionTypeList": [
    {
      "accessionType": [
        "gen"
      ]
    }
  ],
  "dateOfCompletion": [
    "2014-06-15"
  ],
  "dateOfCreation": [
    "2013-09-16"
  ],
  "firstIndexDate": [
    "2013-09-17"
  ],
  "fullTextReceivedDate": [
    "2013-09-15"
  ],
  "electronicPublicationDate": [
    "2013-09-05"
  ],
  "firstPublicationDate": [
    "2013-09-05"
  ]
}